David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.
Commentary|Videos|March 3, 2026
Dr Pearson on Daily Applications of AI in Clinical Practice
Author(s)Alexander T. Pearson, MD, PhD
Fact checked by: Kyle Doherty
Alexander T. Pearson, MD, PhD, discusses how he uses AI in his current daily practice.
Advertisement
Alexander T. Pearson, MD, PhD, outlines AI tools that he uses in his current practice, including ambient dictation. He emphasizes how this technology enables him to focus on interactions with patients rather than meticulous note taking while still being able to achieve digestible and accurate notes of the visit.
Advertisement
Related to this article
Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
IDMC Recommends Continuation of Phase 2 MRD Study of IMNN-001 in Advanced Ovarian Cancer
3
Dr Mayer on the FDA Approval of Camizestrant for ESR1-Mutated Breast Cancer
4
UCSF Breast Cancer Specialists Share Expertise on Challenging Breast Cancer Type
5